Connection

Michael Hallek to Chromosome Deletion

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Chromosome Deletion.
Michael Hallek
Connection Strength
1.710
Chromosome Deletion
  1. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
    View in: PubMed
    Score: 0.787
  2. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 Sep; 92(9):946-965.
    View in: PubMed
    Score: 0.691
  3. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009 Sep 24; 114(13):2589-97.
    View in: PubMed
    Score: 0.099
  4. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
    View in: PubMed
    Score: 0.046
  5. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
    View in: PubMed
    Score: 0.045
  6. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun. 2017 07 28; 8(1):153.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.